Abstract:Inflammation is central to pathogenic processes in diabetes mellitus and the metabolic syndrome and particularly implicates innate immunity in the development of complications. Inflammation is a primary event in Type 1 diabetes where infectious (viral) and/or autoimmune processes initiate disease; in contrast, chronic inflammation is typical in Type 2 diabetes and is considered a sequel to increasing insulin resistance and disturbed glucose metabolism. Diabetic retinopathy (DR) is perceived as a vascular and neurodegenerative disease which occurs after some years of poorly controlled diabetes. However, many of the clinical features of DR are late events and reflect the nature of the retinal architecture and its cellular composition. Retinal microvascular disease is, in fact, an early event pathogenetically, induced by low grade, persistent leukocyte activation which causes repeated episodes of capillary occlusion and, progressive, attritional retinal ischemia. The later, overt clinical signs of DR are a consequence of the retinal ischemia. Metabolic dysregulation involving both lipid and glucose metabolism may lead to leukocyte activation. On a molecular level, we have shown that macrophage-restricted protein tyrosine phosphatase 1B (PTP1B) is a key regulator of inflammation in the metabolic syndrome involving insulin resistance and it is possible that PTP1B dysregulation may underlie retinal microvascular disease. We have also shown that adherent CCR5<sup>+</sup>CD11b<sup>+</sup> monocyte macrophages appear to be selectively involved in retinal microvascular occlusion. In this review, we discuss the relationship between early leukocyte activation and the later features of DR, common pathogenetic processes between diabetic microvascular disease and other vascular retinopathies, the mechanisms whereby leukocyte activation is induced in hyperglycemia and dyslipidemia, the signaling mechanisms involved in diabetic microvascular disease, and possible interventions which may prevent these retinopathies. We also address a possible role for adaptive immunity in DR. Although significant improvements in treatment of DR have been made with intravitreal anti-VEGF therapy, a sizeable proportion of patients, particularly with sight-threatening macular edema, fail to respond. Alternative therapies targeting inflammatory processes may offer an advantage.

CURRENT VIEW ON PATHOGENIC MECHANISMS OF DIABETIC RETINOPATHY

Inflammatory Machenism in the Pathogenesis of Diabetic Retinopathy

MECHANISMS OF DEVELOPMENT AND MODERN DIRECTIONS OF TREATMENT OF DIABETIC RETINOPATHY (literature review)

Diabetic Retinopathy: The Role of Mitochondria in the Neural Retina and Microvascular Disease

The Role of Inflammation in Diabetic Retinopathy

Retinal Vascular Endothelial Cell Dysfunction and Neuroretinal Degeneration in Diabetic Patients

An overview of the pathogenesis of diabetic retinopathy

The pathophysiological mechanisms underlying diabetic retinopathy

Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets

A New Player in the Pathogenesis of Diabetic Retinopathy?

Relationship between Biochemical Pathways and Non-Coding RNAs Involved in the Progression of Diabetic Retinopathy

Search for biomarkers of diabetic retinopathy and its complications in the vitreous body and intraocular fluid

Markers of Proliferative Diabetic Retinopathy

Diabetic Retinopathy: Vascular and Inflammatory Disease

Diabetic retinopathy: an inflammatory disease

Oxidative Stress-Related Mechanisms and Antioxidant Therapy in Diabetic Retinopathy

Current understanding of the molecular and cellular pathology of diabetic retinopathy

Metabolic Memory: Mechanisms and Implications for Diabetic Retinopathy

Implications of Diabetes-Induced Altered Metabolites on Retinal Neurodegeneration

Molecular mechanisms of diabetic retinopathy: Potential therapeutic targets

The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy-A Review